Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors

Abstract

High Resolution Image Download MS PowerPoint Slide KRAS G12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-“undruggable” target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRAS G12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRAS G12C inhibitor currently in phase I clinical trials (NCT03600883).

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b01180

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 2

  1. 10.1016/j.cell.2018.01.006 · DOI · Paper page
  2. Atropisomer interconversion was monitored by 1 H NMR. Exchange rates were calculated from line-shape analysis, coalescence temperatures, or half-lives. Free energy barriers (Δ G ⧧ ) were calculated from exchange rates using Eyring’s equation. For details, see Claridge, T. D. W. High-Resolution NMR Techniques in Organic Chemistry , 3rd ed. Elsevier: Amsterdam, The Netherlands, 2016; p 50.

Cited by

See all 791

Metadata

Authors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., Kopecky, D. J., Liu, L., Lopez, P., Low, J. D., Ma, V., Minatti, A. E., Nguyen, T. T., Nishimura, N., Pickrell, A. J., Reed, A. B., Shin, Y., Siegmund, A. C., Tamayo, N. A., Tegley, C. M., Walton, M. C., Wang, H.-L., Wurz, R. P., Xue, M., Yang, K. C., Achanta, P., Bartberger, M. D., Canon, J., Hollis, L. S., McCarter, J. D., Mohr, C., Rex, K., Saiki, A. Y., San Miguel, T., Volak, L. P., Wang, K. H., Whittington, D. A., Zech, S. G., Lipford, J. R., & Cee, V. J.
Affiliations
Amgen (United States) (US)
Corresponding author
Lanman, Brian A.
Venue
Journal of Medicinal Chemistry
Published
2019-12-10
Volume
63
Issue
1
Pages
52-65
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4231423004
Cited by
765
References
18
Citations by year
2026: 121 · 2025: 138 · 2024: 141 · 2023: 141 · 2022: 117 · 2021: 69 · 2020: 38
FWCI
19.10
Type
journal article
Language
en
Open access
closed
Locations
Journal of Medicinal Chemistry (publishedVersion)
Funders
Howard Hughes Medical Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
KRAS G12C, covalent inhibitors, sotorasib, quinazolinone derivatives, structure-based drug design, axially chiral biaryls, configurational stability, cryptic pocket, solid tumors, undruggable targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b01180
The paper
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., Kopecky, D. J., Liu, L., Lopez, P., Low, J. D., Ma, V., Minatti, A. E., Nguyen, T. T., Nishimura, N., Pickrell, A. J., . . . Cee, V. J. (2020). Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b01180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.